Introduction
Acute GVHD (aGVHD) is a multifactorial disorder resulting in high rates of morbidity and mortality in patients undergoing allo-SCT. Initial treatment usually includes high-dose glucocorticosteroids, resulting in response rates ranging from B30 to 70%. Outcome for patients failing first-line therapy with glucocorticosteroids is poor. [1] [2] [3] Despite extensive research over the years, the pathophysiology of aGVHD is still not well understood. A multistep process was suggested from the study of murine GVHD models. 4 According to this hypothesis, initial release of proinflammatory cytokines results in priming of an immune response through host APCs and proliferation of donor T cells. [5] [6] [7] Subsequently, alloreactive T cells migrate to GVHD target tissues (for example, skin, gut and liver) after undergoing further expansion and differentiation to Th1/Tc1 or Th2/Tc2 cells. 8 Destruction of target tissues is mediated through recruitment of effector leukocytes expressing cell surface and soluble immune effector molecules (for example, Fas ligand, TNF-a, TNF-related apoptosis-inducing ligand (TRAIL), perforin, granzymes and IFN-g), resulting in apoptosis of the epithelial target cells. 9, 10 However, steroid exposure induces a rapid decline of T-lymphocyte turnover, both systemically and locally, in the affected tissues. Therefore, steroid-resistant GVHD cannot be explained by tissue-infiltrating, alloreactive T lymphocytes alone.
Pentostatin (deoxycoformycin), a purine analogue, is a potent inhibitor of T-cell proliferation and function by blocking adenosine deaminase. 11 Congenital absence of adenosine deaminase in humans leads to SCID syndrome. 12 Adenosine deaminase deficiency/inhibition has furthermore been shown to result in an accumulation of adenosine, a nucleoside not only necessary in DNA synthesis but also an important signalling molecule. Activation of the G-proteincoupled adenosine receptor A2A has been linked to downregulation of proinflammatory cytokines in both lymphocytes and macrophages. 13 Interestingly, pentostatin has recently been shown to reduce inflammation in inflammatory bowel disease in a mouse model by impairing effector T-cell expansion and reducing proinflammatory cytokine production, while preserving regulatory T-cell populations and function.
14 Blocking several important pathophysiological pathways of aGVHD with pentostatin thereby seems an intriguing approach. Known side effects (for example, neutropenia, anemia, thrombocytopenia, nausea and emesis) from previous use in other hematological malignancies are usually mild. 15, 16 In a mouse model, pretreatment with pentostatin was able to prevent aGVHD after allogeneic BMT and resulted in longer OS. 17 However, published clinical data on the value of pentostatin in this indication is sparse. In a phase I clinical trial, Bolan˜os-Meade et al. 18 were able to achieve CR rates of up to 63% with pentostatin in the treatment of steroidrefractory aGVHD. Klein et al. 19 showed a similar CR rate of 61% with a long-term survival of 39%. On the basis of these results and in the absence of alternative evidencebased approaches, we adopted pentostatin as standard firstline salvage treatment for steroid-refractory intestinal GVHD in our center. Here, we present a retrospective analysis of our experience with particular focus on the short-term toxicity of this strategy.
Patients and methods
All patients who had been treated at the University of Heidelberg with pentostatin for intestinal GVHD subsequent to allo-SCT between February 2005 and December 2008 were identified and retrospectively analyzed. GVHD staging and grading were performed according to the updated Glucksberg criteria. 20 Following internal standard operating procedures, patients with biopsy-proven acute GVHD of the gastrointestinal (GI) tract with overall GVHD grades III-IV unresponsive to at least 3 days of prednisone (2 mg/kg) were eligible for pentostatin administration. Non-response to steroids was defined as no reduction in stool volume after at least 3 days of prednisone (2 mg/kg). Intestinal GVHD was considered as being 'acute' if the clinical appearance of acute-onset profuse diarrhea was present independent of the time interval after allo-SCT. 21 After obtaining written informed consent, pentostatin was administered at a daily dose of 1 mg/m 2 i.v. over 3 consecutive days. Dosing and schedule was adopted from a previous trial of pentostatin for this indication. 19 The rationale was that a dose of 1 mg/m 2 over 3 consecutive days had been well tolerated, and was as effective as higher doses in the prospective trial and in the retrospective analysis. 18, 19 Pentostatin could be repeated from day þ 14 after the first dose onward in case of incomplete response (defined as not reaching CR or very good PR, see below) or recurrence of GVHD (defined as flare of symptoms after initial response). Prednisone was maintained at 2 mg/kg for the first 4 days after start of pentostatin treatment, and then tapered by 20% every 4 days.
There is currently no widely accepted consensus on response criteria for GVHD accurately reflecting the clinical benefit for the patient. For the purpose of this analysis, we adopted the definitions recently proposed by an expert consortium in a position paper. 22 CR required completely resolved diarrhea for at least 1 month, whereas very good PR (VGPR) required that patients tolerated food or enteral feeding, and had predominantly formed stools, no overt GI tract bleeding or abdominal cramping and no more than occasional nausea or vomiting. All other patients were classified as nonresponders. According to the suggestions of the position paper, 22 we omitted considering PRs, as those are difficult to define and of questionable clinical value. Patients were evaluated daily for treatment response, and final response assessment was standardized on day þ 28 after pentostatin treatment in surviving patients.
Short-term hematological, renal and hepatotoxicity was retrospectively assessed by comparing WBC, plts, total serum bilirubin, alanine aminotransferase, creatinine and C-reactive protein values immediately before pentostatin administration, and 7 and 14 days after the first dose from electronically filed patient charts. Major clinical toxicities occurring after pentostatin administration were collected by chart review, including reactivation of CMV. Donorrecipient matching status was determined by four-digit HLA genotyping performed for HLA-A, HLA-B, HLA-C, HLA-DQ and HLA-DR. A 'matched' donor required complete concordance at the allele level on all 10 loci.
The Mann-Whitney test was used to compare routine laboratory parameters between days 0, 7 and 14, after start of pentostatin treatment. Response rates between subgroups of patients were compared using Fisher's exact test. Survival time data were measured from the time of the first dose of pentostatin. Survival curves were estimated using the method of Kaplan and Meier. Significance levels were set at 0.05. Calculations were carried out using GraphPad Prism software (release 5.02; San Diego, CA, USA). Data were analyzed as of 31 October 2009.
Results
Between February 2005 and December 2008, a total of 24 patients (out of 301 patients who underwent transplantation during that time interval and 25 patients treated with pentostatin only) received pentostatin for first-line salvage treatment of steroid-refractory GI GVHD. Diagnoses included ALL (n ¼ 2), AML (n ¼ 10), myelodysplastic syndromes (n ¼ 3), lymphoma (n ¼ 6) and multiple myeloma (n ¼ 3). Gender was well balanced (male, n ¼ 13 and female, n ¼ 11) with a median age of 50 (23-64) years. All transplants were PBSCs from matched siblings (n ¼ 8), matched unrelated (n ¼ 4) or mismatched donors (n ¼ 12). Conditioning regimens were fully myeloablative (containing 12 Gy TBI or 16 mg per kg BU) in 7 patients and reduced intensity in 17 patients. The indication for pentostatin was acute GI GVHD with organ grades being 2 (n ¼ 3), 3 (n ¼ 11) and 4 (n ¼ 10), corresponding to overall GVHD grade III in 13 patients and overall grade IV in 11 patients. There was no case of donor lymphocyte infusioninduced steroid-refractory GVHD in this series, but in three patients (UPN 496, UPN 525 and UPN 559) GVHD occurred subsequent to rapid CsA taper triggered by relapse of the underlying malignancy. The median time interval from transplant to GVHD was 78 (5-211) days, and the median time interval from start of prednisone to start of pentostatin was 10 (3-42) days. The patient with the 42-day interval (UPN 413) responded initially to steroid treatment, but experienced a flare of symptoms requiring salvage treatment. Patients received one (n ¼ 16) or two (n ¼ 8) cycles of pentostatin (1 mg/m 2 i.v. once daily on days 1-3). Details are given in Table 1 .
After pentostatin administration, complete resolution of acute GI GVHD at day þ 28 was observed in five patients, with a median time to response of 6 days (3-10). VGPR was observed in four additional patients evaluable 28 days after pentostatin administration. Four patients died within Pentostatin for steroid-refractory GVHD T Schmitt et al 14 days after start of pentostatin administration and were counted as nonresponders, although one patient, dying at day þ 20 because of infection, otherwise fulfilled the criteria of VGPR. Therefore, the overall response rate in all 24 patients was 38%, with a median time to response of 10 days. The response rate tended to be higher in matched sibling recipients than in unrelated or mismatched donor recipients (63 vs 25%; P ¼ 0.099). Of note, the time interval between start of prednisone and start of pentostatin was longer in responding patients than in nonresponders (12 days (4-42) vs 6 days (3-17); P ¼ 0.055). The time interval between allo-SCT and GVHD, as well as conditioning intensity had no impact on response probability. Whereas significant or clinically meaningful changes in WBC, creatinine and C-reactive protein did not occur, moderate increases in total serum bilirubin and alanine aminotransferase, as well as decreasing plts were observed 1 and 2 weeks after pentostatin administration (Table 2 ). There were six early fatalities 5-20 days after pentostatin administration owing to ongoing GVHD with multiorgan failure (UPN 352, UPN 410, UPN 489 and UPN 537) or progressive underlying lymphoma (UPN 559) and sepsis despite VGPR (UPN 419) ( Table 1) . CMV reactivation after pentostatin administration was observed in 44% of patients at risk (8/18) after a median time of 8 days (3-11). In total, 22% of subjects (4/18) suffered from CMV reactivation before pentostatin administration within a median time of 4 (2-6) days. All patients failing to respond to pentostatin also failed to respond to eventual further salvage therapies, including MSCs, tacrolimus, basiliximab, rituximab and infliximab, and died. Of the nine responders, four patients subsequently died because of infection, one died of recurrent GVHD and one of relapse of the underlying malignancy, translating into an OS rate of 25% at 6 months and 17% at 2 years ( Figure 1 ).
Discussion
Here, we report on our single-center experience using pentostatin for steroid-refractory GVHD. A CR/VGPR rate of 38% was observed after a median time to response of 10 days. In comparison with the two previously published small pentostatin series, in which CR rates above 60% were reported, 18, 19 the overall response rate in our series seems to be lower. Adverse factors that may have affected the response rate here are the high proportion of mismatched donors and the exclusive inclusion of overall grade III-IV disease with advanced GI involvement.
However, the overall results are comparable with other clinically used second-line salvage treatments. Van Lint et al.
1 treated 211 patients with grade I-IV aGVHD with methylprednisolone (2 mg/kg). Of these, 29% had not responded by day 5 and were randomized to receive escalated methylprednisolone (5 mg/kg) with or without antithymocyte globulin. The overall response rate was 49% without any effect of antithymocyte globulin.
In an uncontrolled phase II trial, OKT3 muromonab, a MoAb directed against CD3, achieved a response rate of 69% but a considerably lower CR rate of only 12%. 23 A slight advantage of addition of OKT3 to high-dose steroids has been confirmed in a subsequent phase III trial. 24 Other phase II studies that addressed blocking of proinflammatory cytokines (for example, TNF-a and IL-2) with MoAbs resulted in overall CR rates of 47, 53 and 62% for daclizumab, basiliximab and infliximab, respectively. [25] [26] [27] In the study by Przepiorka et al. using daclizumab, a specific CR rate of 37% was reported for GI GVHD. A CR rate of 67% was reported for infliximab by Couriel et al. However, only 3 of 12 subjects had grade X3 GI GVHD. A more recent larger study in a series of 52 patients showed a disappointing 15% CR rate with a 2-year OS of less than 10%. 28 Extracorporal photochemotherapy has been reported to induce CRs in up to 61 and 40% of patients with GI aGVHD, respectively, depending on GVHD grade. 29, 30 The use of MSCs has been of emerging interest in the treatment of aGVHD because of their immunoregulatory potential. Le Blanc et al. 31 achieved CR rates of 55% (30/55) in a phase II study. Patients responding to therapy with MSCs also had a significantly higher chance of survival at 2 years with 52% CR rate. No specific response rate for GI GVHD was reported, and differences according to GVHD grade and multiorgan involvement did not reach statistical significance. In contrast, a CR rate of only 15% was observed in a recent series of patients with refractory aGVHD treated with plt lysate-conditioned MSCs. 32 A large randomized phase III trial involving 244 patients with steroid-refractory GVHD revealed a trend in favor of the addition of MSCs to the salvage regimen in the per protocol population in comparison with placebo (CR 40 vs 28%; P ¼ 0.08). 33 Taken together, in the absence of convincing results from randomized phase III trials, it seems that there is no salvage treatment for steroid-refractory GI aGVHD with obviously outstanding efficacy. Therefore, secondary criteria might be considered when choosing the therapeutic regimen. In our experience, advantages of pentostatin are cost-effectiveness, easy application and (more speculative) its potential additional antitumour effect. Moreover, short-term toxicity, as assessable by routine blood count and chemistry monitoring, seems to be mild. Although pentostatin is a myelosuppressive agent, the regimen used here was not associated with significant changes in WBC count, creatinine and C-reactive protein. The observed changes in total serum bilirubin and alanine aminotransferase were moderate and most likely because of the multidrug regimens used in this critically ill patient population and/or progression of liver GVHD in nonresponders. However, direct hepatotoxic effects of pentostatin have been described. 15 The decrease of plts that we observed could be a consequence of pentostatin, but it might also be aggravated by ongoing GVHD.
Nevertheless, six patients experienced early death (within 3 weeks) after pentostatin, and five of the nine responders died because of infectious complications or recurrent GVHD later on. Although the early fatalities were probably attributable to the overall poor performance status of the patients, and thus to a certain degree a consequence of lack of response to pentostatin, a toxic effect of the drug cannot be excluded. Similarly, the high risk of infection-related death in the responders raises some concern. Given the high rate of CMV reactivations, patients should be closely monitored. As in our series CMV reactivations were also observed before the administration of pentostatin, this is probably not a drug-specific effect, but a consequence of the prolonged immunosuppression.
Patients allografted from HLA-identical sibling donors tended to do better than unrelated or mismatched recipients. Unexpectedly, responders had a longer duration of the steroid-refractory status before pentostatin administration, suggesting that they might represent a more favorable population with less demand for immediate second-line therapy.
In conclusion, pentostatin is an easy-to-use second-line treatment for GI aGVHD, showing response and outcome rates not apparently different from other clinically used regimens. However, with a long-term survival of only 17% at 2 years, outcome is still dismal. Clinical investigations aiming at more effective treatment approaches or prevention strategies for steroid-refractory GVHD are therefore urgently needed. 34 
